Active substance
Medroxyprogesterone
- SFDA 6
- US FDA 25
- Health Canada 8
- US price lines 8
- NHS prices 10
- WHO EML 2
- Safety 9
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DEPO-PROVERA VIAL I-M 150MG-ML | 150 mg/ml | Suspension for injection · Intramuscular use | 1 Vial | SAR 42.55 | NCE · Prescription | PFIZER | Valid |
| PROVERA 5MG TAB | 5 mg | Tablet · Oral use | 24 Bottle | SAR 34.65 | NCE · Prescription | PFIZER ITALY S.R.I | Valid |
| DEPO-PROVERA VIAL I-M 150MG-ML | 150 mg/ml | Suspension for injection · Intramuscular use | 1 Vial | SAR 94.05 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| FARLUTAL 250MG TAB | 250 mg | Tablet · Oral use | 30 Tablet Container | SAR 145.25 | Generic · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| PROVERA 100MG TAB | 100 mg | Tablet · Oral use | 100 Tablet Container | SAR 273.55 | NCE · Prescription | PHARMACIA UPJOHN | Withdrawn by MAH · Not Marketed |
| PROVERA 5MG TAB | 5 mg | Tablet · Oral use | 24 Bottle | SAR 17.25 | NCE · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CONTRACEPTION; ENDOMETRIAL CANCER; ENDOMETRIOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| PROVERA | 2.5MG; 5MG; 10MG | tablet · oral | PFIZER | Prescription | 18 Jun 1959 |
| DEPO-PROVERA | 150MG/ML | injectable · injection | PFIZER | Prescription | 29 Oct 1992 |
| MEDROXYPROGESTERONE ACETATE | 2.5MG; 5MG; 10MG | tablet · oral | BARR | Prescription | 9 Aug 1996 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | HONG KONG | Prescription | 28 Jul 2004 |
| DEPO-SUBQ PROVERA 104 | 104MG/0.65ML | injectable · subcutaneous | PFIZER | Prescription | 17 Dec 2004 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | AMPHASTAR PHARMS INC | Prescription | 28 Nov 2017 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | AMPHASTAR PHARMS INC | Prescription | 28 Nov 2017 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | XIROMED | Prescription | 12 Oct 2018 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 22 Aug 2022 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | EUGIA PHARMA | Prescription | 31 Aug 2022 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | AMNEAL | Prescription | 7 Jun 2023 |
| DEPO-PROVERA | 100MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 400MG/ML | injectable · injection | PFIZER | Discontinued | 23 Sep 1960 |
| AMEN | 10MG | tablet · oral | AMARIN PHARMS | Discontinued | 15 May 1974 |
| CURRETAB | 10MG | tablet · oral | SOLVAY | Discontinued | 28 Apr 1978 |
| MEDROXYPROGESTERONE ACETATE | 10MG | tablet · oral | UPSHER SMITH LABS | Discontinued | 26 Jul 1984 |
| CYCRIN | 10MG | tablet · oral | ESI | Discontinued | 9 Sep 1987 |
| CYCRIN | 2.5MG | tablet · oral | ESI | Discontinued | 30 Oct 1992 |
| CYCRIN | 5MG | tablet · oral | ESI | Discontinued | 30 Oct 1992 |
| MEDROXYPROGESTERONE ACETATE | 2.5MG; 5MG; 10MG | tablet · oral | DURAMED PHARMS BARR | Discontinued | 1 Dec 1999 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | TEVA PHARMS USA | Discontinued | 27 Oct 2004 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | SANDOZ | Discontinued | 20 May 2009 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | CIPLA | Discontinued | 25 Jan 2019 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | SUN PHARM | Discontinued | 24 Apr 2019 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | SUN PHARM | Discontinued | 1 May 2019 |
| MEDROXYPROGESTERONE ACETATE | 150MG/ML | injectable · injection | HIKMA PHARMS | Discontinued | 5 Jan 2023 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-MEDROXY | 02244726 | 2.5 MG | TABLET · ORAL | AA PHARMA INC |
| AA-MEDROXY | 02244727 | 5 MG | TABLET · ORAL | AA PHARMA INC |
| AA-MEDROXY | 02267640 | 100 MG | TABLET · ORAL | AA PHARMA INC |
| AA-MEDROXY | 02277298 | 10 MG | TABLET · ORAL | AA PHARMA INC |
| DEPO-PROVERA | 02523493 | 150 MG / ML | SUSPENSION · INTRAMUSCULAR | PFIZER CANADA ULC |
| TEVA-MEDROXYPROGESTERONE | 02221284 | 2.5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-MEDROXYPROGESTERONE | 02221292 | 5 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| TEVA-MEDROXYPROGESTERONE | 02221306 | 10 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DEPO-PROVERA 150 MG/ML SYRINGE | $52.335 | per ML | 23 Sep 2026 |
| US NADAC | DEPO-PROVERA 150 MG/ML VIAL | $50.994 | per ML | 22 Apr 2026 |
| US NADAC | MEDROXYPROGESTERONE 10 MG TAB | $0.1523 | per EA | 23 Sep 2026 |
| US NADAC | MEDROXYPROGESTERONE 150 MG/ML | $18.85351 | per ML | 23 Sep 2026 |
| US NADAC | MEDROXYPROGESTERONE 150 MG/ML | $22.84953 | per ML | 23 Sep 2026 |
| US NADAC | MEDROXYPROGESTERONE 150 MG/ML | $27.36384 | per ML | 23 Sep 2026 |
| US NADAC | MEDROXYPROGESTERONE 2.5 MG TAB | $0.11556 | per EA | 23 Sep 2026 |
| US NADAC | MEDROXYPROGESTERONE 5 MG TAB | $0.14277 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Medroxyprogesterone 100mg tablets | £49.94 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 104mg/0.65ml suspension for injection pre-filled disposable devices | £6.90 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 10mg tablets | £2.47 | 10 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 10mg tablets | £22.16 | 90 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 10mg tablets | £24.73 | 100 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 150mg/1ml suspension for injection pre-filled syringes | £6.01 | 1 pre-filled disposable injection | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 2.5mg tablets | £1.84 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 200mg tablets | £29.65 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 400mg tablets | £58.67 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Medroxyprogesterone 5mg tablets | £1.23 | 10 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.1.2. Injectable hormonal contraceptives · core
Contact with health services for reasons associated with reproduction
Parenteral > General injections > IM: 150 mg per mL in 1 mL vial | Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system - 18.4. Progestogens · core
Excessive menstruation with irregular cycle
Oral > Solid: 5 mg
Safety signals and safety-related labeling changes
- US FDA 12 Dec 2025 DEPO-SUBQ PROVERA 104 — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 12 Dec 2025 DEPO-PROVERA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Apr 2025 PREMPHASE 14/14 — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 22 Apr 2025 PREMPRO — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 5 Sep 2024 PRAC signal: Meningioma
Action for MAH: update of the product information: Yes - EMA PRAC 13 Jun 2024 PRAC signal: Meningioma
Action for MAH: update of the product information: No - US FDA 15 Feb 2024 PROVERA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 8 Feb 2024 PRAC signal: Meningioma
Action for MAH: update of the product information: No - US FDA 3 Apr 2017 DEPO-PROVERA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.